A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 inA vitro but does not protect a mouse model from disease

Amanda E. Calvert, Kandice L. Dixon, Joseph Piper, Susan L. Bennett, Brett A. Thibodeaux, Alan Barrett, John T. Roehrig, Carol D. Blair

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The yellow fever virus (YFV) vaccine 17D-204 is considered safe and effective, yet rare severe adverse events (SAEs), some resulting in death, have been documented following vaccination. Individuals exhibiting post-vaccinal SAEs are ideal candidates for antiviral monoclonal antibody (MAb) therapy; the time until appearance of clinical signs post-exposure is usually short and patients are quickly hospitalized. We previously developed a murine-human chimeric monoclonal antibody (cMAb), 2C9-cIgG, reactive with both virulent YFV and 17D-204, and demonstrated its ability to prevent and treat YF disease in both AG129 mouse and hamster models of infection. To counteract possible selection of 17D-204 variants that escape neutralization by treatment with a single MAb (2C9-cIgG), we developed a second cMAb, 864-cIgG, for use in combination with 2C9-cIgG in post-vaccinal therapy. MAb 864-cIgG recognizes/neutralizes only YFV 17D-204 vaccine substrain and binds to domain III (DIII) of the viral envelope protein, which is different from the YFV type-specific binding site of 2C9-cIgG in DII. Although it neutralized 17D-204 inA vitro, administration of 864-cIgG had no protective capacity in the interferon receptor-deficient AG129 mouse model of 17D-204 infection. The data presented here show that although DIII-specific 864-cIgG neutralizes virus infectivity inA vitro, it does not have the ability to abrogate disease inA vivo. Therefore, combination of 864-cIgG with 2C9-cIgG for treatment of YF vaccination SAEs does not appear to provide an improvement on 2C9-cIgG therapy alone.

Original languageEnglish (US)
Pages (from-to)92-99
Number of pages8
JournalAntiviral Research
Volume131
DOIs
StatePublished - Jul 1 2016

    Fingerprint

Keywords

  • Monoclonal antibody therapy
  • Neutralizing antibody
  • Post-vaccinal SAE
  • YFV vaccine

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this